[News] Targeting the B-cell signalling pathway in CLL and MCL

20:41 EDT 27 Jun 2013 | The Lancet

A new class of drugs that inhibit the B-cell signalling pathway could represent a turning point in the treatment of chronic lymphocytic leukaemia and mantle cell lymphoma. Ibrutinib is an oral inhibitor of the Bruton's tyrosine kinase, which is thoug...

Original Article: [News] Targeting the B-cell signalling pathway in CLL and MCL

NEXT ARTICLE

More From BioPortfolio on "[News] Targeting the B-cell signalling pathway in CLL and MCL"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

The top 5 most promising drugs (February 2014)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS LAUNCHED OR RECEIVING APPROVAL February 2014 Drug Disease Company Gazyva™ Chronic lymphocytic leukemia Biogen Idec/Genentech/ F. Hoffman-La Roche ...

Advertisement

Searches Linking to this Story